My watch list  

NorDiag ASA

Thormøhlensgate 55
5008 Bergen

Company Portrait

NorDiag is a biotechnology company with focus on genebased diagnostics in the fields of cancer and infectious diseases for human disease. The Company's first product in cancer detection is Genefec™ for the early diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline.

Focus: Manufacturer

Industrial Sectors

  • Diagnostics
More about NorDiag
  • News

    Researchers identify non-culturable microbes from bloodstream infections

    Molzym has developed in collaboration with NorDiag ASA the first automated platform worldwide for the culture-independent universal identification of microorganisms from whole blood. Clinical studies have shown that a high proportion of microbial infections are not detectable by conventiona ... more

    Cooperation between NorDiag and Molzym

    NorDiag and Molzym have now succeeded to combine their respective technologies into an integrated system for automated molecular detection of pathogens, among others for sepsis testing. Following this milestone, the two companies have signed a firm collaboration agreement regarding sale of ... more

    NorDiag enters distribution and collaboration agreement with Molzym

    NorDiag has entered into two distribution agreements with German based Molzym GmbH & Co KG covering Molzym’s molecular diagnostic products. The first agreement is geographically restrained to USA and Canada, while the second agreement covers the Nordic countries. NorDiag has also entered i ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE